Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBT: 2010-2024

Historic EBT for Northwest Biotherapeutics (NWBO) over the last 15 years, with Dec 2024 value amounting to -$74.3 million.

  • Northwest Biotherapeutics' EBT fell 0.36% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 5.42%. This contributed to the annual value of -$74.3 million for FY2024, which is 22.27% down from last year.
  • Northwest Biotherapeutics' EBT amounted to -$74.3 million in FY2024, which was down 22.27% from -$60.7 million recorded in FY2023.
  • Over the past 5 years, Northwest Biotherapeutics' EBT peaked at -$57.7 million during FY2021, and registered a low of -$95.1 million during FY2020.
  • Its 3-year average for EBT is -$69.4 million, with a median of -$73.2 million in 2022.
  • As far as peak fluctuations go, Northwest Biotherapeutics' EBT plummeted by 207.39% in 2020, and later spiked by 39.34% in 2021.
  • Northwest Biotherapeutics' EBT (Yearly) stood at -$95.1 million in 2020, then surged by 39.34% to -$57.7 million in 2021, then fell by 26.92% to -$73.2 million in 2022, then rose by 17.07% to -$60.7 million in 2023, then declined by 22.27% to -$74.3 million in 2024.